NCT04013685进行中（未招募）1 期
A Phase Ib Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 155
- 试验地点
- 33
- 主要终点
- The incidence of primary graft failure
研究概览
简要总结
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Recipients must meet all of the following criteria:
- •Patients must be diagnosed with 1 of the following histopathologically confirmed diseases, for which a myeloablative hematopoietic stem cell transplant (HCT) is planned:
- •A) Acute myeloid, lymphoid, or mixed phenotype/undifferentiated leukemia who are not in CR or CRi (active disease) and/or MDS with >10% to <20% bone marrow blast burden (ages 18 to 75 years)
- •B) Acute leukemia in CR/CRi or MDS that is DRI intermediate to high risk (ages 66 to 75 years)
- •C) BPDCN (ages 18 to 65 years)
- •D) Participants aged 18 to 65 who would be eligible for the Phase 3 component of Precision-T except for mild impairments of renal and/or hepatic function as defined by an eGFR of 50 to <60 mL/min and/or a total bilirubin of >ULN to ≤2 x ULN and diagnosed with either of the following:
- •i. Acute myeloid, lymphoid, or mixed phenotype/undifferentiated leukemia that is in CR/CRi and DRI intermediate to high risk
- •a) MDS that is DRI intermediate to high risk
- •E) Acute or chronic leukemia in remission that is DRI low risk (ages 18 to 65 years), including the following:
- •i. CML in chronic phase but with a history of accelerated phase or blast crisis or who are resistant to or intolerant of more than 1 first- and second-generation tyrosine kinase inhibitors
- •ii. Acute myeloid leukemia (AML) with inv(16) without accompanying complex cytogenetics
- •Patients must be matched to a 8/8 HLA-matched related or unrelated donor
- •Estimated glomerular filtration rate (eGFR) >50 mL/minute
- •Cardiac ejection fraction at rest ≥45% or shortening fraction of ≥27% by echocardiogram or radionuclide scan (MUGA)
- •Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥50%
- •Total bilirubin <2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included where hemolysis has been excluded) and ALT/AST <3 times ULN
排除标准
- •Recipients meeting any of the following exclusion criteria will not be eligible:
- •History of prior allogeneic HCT
- •Currently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed.
- •Pre-planned donor lymphocyte infusion (DLI)
- •Planned pharmaceutical in vivo or ex vivo T cell depletion
- •Positive for anti-donor HLA antibodies against an allele in the selected donor
- •Karnofsky performance score <70%
- •Hematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) >4
- •Uncontrolled bacterial, viral or fungal infections (currently taking antimicrobial therapy and with progression or no clinical improvement) at time of enrollment
- •Seropositive for HIV-1 or -2 antibody, HTLV-1 or -2 antibody, Hepatitis B sAg, or Hepatitis C antibody
- •Any uncontrolled autoimmune disease requiring active immunosuppressive treatment
- •Concurrent malignancies or active disease within 1 year, except non-melanoma skin cancers that have been curatively resected
- •Women who are pregnant or breastfeeding
研究组 & 干预措施
Subjects with Acute Leukemia or Myelodysplastic Syndrome, or BPDCN
Experimental
This is a non-randomized, single-arm study. All enrolled subjects will receive an allogeneic HCT with the Orca-T product.
干预措施: Orca-T (Biological)
结局指标
主要结局
The incidence of primary graft failure
时间窗: 365 days
The incidence of primary graft failure
The incidence of grade 3 or 4 aGVHD
时间窗: 180 days
The incidence of grade 3 or 4 aGVHD
次要结局
- 1 year graft-versus-host-disease-free and relapse-free survival (GRFS)(365 days)
- 1-year overall survival (OS)(365 days)
- incidence and severity of acute and chronic graft vs host disease (GvHD)(365 days)
- incidence of serious infections(365 days)
- incidence of engraftment(28 days)
研究者
研究点 (33)
Loading locations...
相似试验
进行中（未招募）
3 期
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesAcute Lymphoid LeukemiaUndifferentiated LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute LeukemiaTherapy-Related Myelodysplastic SyndromeAcute LeukemiaMyelodysplastic SyndromeNCT05316701Orca Biosystems, Inc.187
招募中
1 期
Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCTAcute Lymphoid LeukemiaMyelodysplastic SyndromesAcute Myeloid LeukemiaMixed Phenotype Acute LeukemiaNCT06551584Stanford University24
已完成
2 期
Mismatched Transplantation Using High-dose Post-transplant CyclophosphamideBlood Stem Cell Transplant FailureHematologic MalignanciesLeukemiaNCT01010217M.D. Anderson Cancer Center176
已完成
2 期
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid NeoplasmsBlasts 10 Percent or More of Bone Marrow Nucleated CellsChronic Myelomonocytic Leukemia-2High Grade Malignant NeoplasmMyelodysplastic Syndrome With Excess Blasts-2Myeloid NeoplasmPreviously Treated Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaMyelodysplastic SyndromeNCT02756572University of Washington30
已完成
2 期
Allogeneic Transplant in HIV Patients (BMT CTN 0903)HIVLymphomaLeukemiaNCT01410344Medical College of Wisconsin20